PHASE II TRIAL OF PACLITAXEL IN PATIENTS WITH ADVANCED COLON CANCER PREVIOUSLY UNTREATED WITH CYTOTOXIC CHEMOTHERAPY: AN EASTERN COOPERATIVE ONCOLOGY GROUP TRIAL (PA286)

Abstract

Paclitaxel was administered as a 24-h continuous infusion at 250 mg/m2 in this Phase II trial in patients with adenocarcinoma of the colon or rectum. Nineteen patients were evaluated for toxicity and 15 were assessable for response. There were no complete or partial responses, and toxicity present was primarily neutropenia. This study found that paclitaxel as a single agent does not have activity in adenocarcinoma of the colon or rectum.